Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
about
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsEarly prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study groupOutcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemiaNumber of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapyThe prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01Biology and management of relapsed acute myeloid leukaemia.Treatment of AML in biological subgroups.Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group.Early gene expression of acute myeloid leukemia in response to chemotherapy.Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Interactive diagnostics in the indication to allogeneic SCT in AML.Acute myeloid leukemia with normal cytogenetics.Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Mesenchymal stromal cells contribute to quiescence of therapy resistant leukemic cells in acute myeloid leukemia.Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Day 14 bone marrow examination in the management of acute myeloid leukemia.Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia.The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.The prognostic value of hematogones in patients with acute myeloid leukemia.Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CTPeripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapyComparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
P2860
Q28073464-7282E97D-00A2-4F04-A2CE-47A79CCB2F4FQ33245160-55EB9088-2FEE-4336-B42E-695F16B5FD2AQ33558123-18E0CBC3-3980-4F2C-9BCB-61C83634DF4EQ33734101-BA587D0F-0DCF-4378-9CE7-66F860018277Q33832709-95320DAD-D49B-437F-BDE1-724F8AC1831BQ33877213-6D1A59D7-3018-4090-ABE3-4679B9F1E6A0Q34279037-A3A13960-9258-469E-8A3A-62A25436C59DQ34979564-9E1B5A27-A20E-4950-89C8-8E1E12E0C6ACQ35869967-80F428AE-8E0F-4748-BF60-CC0395DAD42BQ35886215-B668B34A-01B6-4B49-BB0F-ECDE7ED8AD27Q36036315-BF34E9EB-6273-406E-99B8-3326E1F8CF5CQ36085026-F6C52531-215C-441C-9739-3B41BF3337CDQ36308975-2880A89E-D5BC-4CBA-8990-E2E5BA323912Q36593525-9F602458-F462-48ED-AEE4-665B50BAB513Q36817144-BA7317EC-7422-4F63-A743-28FAADBB8644Q37120335-4316E343-4614-4AEE-8E6D-A8E9920844EBQ37166414-7E488A82-90C2-4C9A-A47C-3F713CAA5E6EQ37284741-F0195E0E-26CB-4E9E-AAAF-5CB1F5FCD8B0Q37323006-D0A02A2A-7A26-4AFC-83DC-7EE048AF4975Q37442649-ADD0A3B1-AA6E-435C-B465-AC82FE6AB11EQ38027047-28D0A739-D7B7-45F8-8DFC-94E438FAAEAAQ38128358-4EE14BF1-F738-4F71-93DC-D08BC003422FQ38183943-02069DA9-D656-432D-9909-16ABC8071362Q38458733-FCFEA453-2782-4112-808C-8B5818615784Q38494659-FB6CE253-5C75-49AC-BD01-92D122A7220BQ38628894-3DE49CDC-B1C6-43B1-9FDB-1A0C2FC76CA0Q38668301-E3A6936B-8C1A-4380-8238-02D47855213DQ38711002-3204AEE5-7125-4E64-9CDB-FE15228F5024Q39071892-7E3AA0CA-C2D1-442C-9E95-7129B3BD84D7Q39132424-DE98BE5A-8CCD-4C0A-9519-82C92259398DQ39371569-4D7B659F-6591-4943-A0C7-FC811FC5FD8FQ39706444-E0397931-94AE-4D11-9D6F-F9D798B44ED1Q40202671-8EC3F90F-E92F-47BF-A138-B8F0854C8CACQ40256523-43631C45-5161-42C2-B7E1-5541493C6031Q40451918-0C667EAC-F0E4-45BF-9FE1-9EF1D05576A3Q40876342-C744E825-A442-44D0-BFDF-29A2BD09BB22Q41683904-24CAA86C-3E89-4736-967B-27323DA7A0B4Q42365051-CA98E35C-CD4E-4FDF-842A-8EC0B29A023CQ42377773-C84BE310-69AC-4581-852E-B1B6EFE7FDF4Q42705834-7054B760-6539-471C-A003-156034F182B8
P2860
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@ast
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@en
type
label
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@ast
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@en
prefLabel
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@ast
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@en
P2093
P1433
P1476
Early blast clearance by remis ...... tive Group (AMLCG) 1992 Trial.
@en
P2093
Achim Heinecke
Helmut Loffler
Maria Christina Sauerland
Thomas Buchner
Winfried Gassmann
Wolfgang Berdel
Wolfgang Hiddemann
Wolfgang Kern
P356
10.1182/BLOOD-2002-02-0532
P407
P577
2002-06-28T00:00:00Z